Latest / Stock Movers / Novo Nordisk's Pill, BMW's Struggle, Diageo Up
Transcript
- 0:02Speaker 1: Bloomberg Audio Studios, Podcasts, Radio News.
- 0:08Speaker 2: The Stock Movers Report, your roundup of companies making moves
- 0:12Speaker 2: in the stock market, harnessing the power of Bloomberg Data
- 0:16Speaker 2: Bestic look.
- 0:17Speaker 3: At some stocks on the move today in Europe. Then
- 0:20Speaker 3: I'm Tom McKenzie with Caroline Hepcutt. We're joined now by
- 0:22Speaker 3: Bloomberg's Breaking News editor Louise Moon. And Louise we've got
- 0:26Speaker 3: the broader market sentiments factory in but also the earning
- 0:28Speaker 3: story a Novo nor Risk, the maker of course of
- 0:31Speaker 3: OBESD drugs benefiting from a dose of optimism.
- 0:34Speaker 4: Indeed, yes, they had their first quarter results and sales
- 0:37Speaker 4: essentially being fueled by their new we Goo v obest pill,
- 0:42Speaker 4: and as a result, they're saying that declines this year
- 0:44Speaker 4: won't be as bad as expected. So they're saying that
- 0:46Speaker 4: the worst drop for the full year profit in sales
- 0:49Speaker 4: will be about twelve percent. They had said about thirteen percent,
- 0:52Speaker 4: so slightly less than.
- 0:54Speaker 1: They had expected.
- 0:55Speaker 4: And this is all part of their race to essentially
- 0:59Speaker 4: catch up and.
- 1:01Speaker 1: With their rival Eli Lilly in America.
- 1:03Speaker 4: So they obviously lost market share originally to Eli Lilly's
- 1:08Speaker 4: shot version and they kind of failed to be there,
- 1:11Speaker 4: failed to capitalize on being first to market with that product,
- 1:14Speaker 4: and so the question is now they can they really
- 1:17Speaker 4: compete with the with this pill version and compete competitively
- 1:21Speaker 4: with with Eli Lilly. So so far it's looking good
- 1:25Speaker 4: and analysts saying that, you know, it's encouraging. There's good
- 1:27Speaker 4: momentum with sales of this pill and it's helping to
- 1:31Speaker 4: should help drive the stock and we're seeing that some
- 1:32Speaker 4: money shares surged in Copenhagen as much as just over
- 1:35Speaker 4: nine percent, So positive news on that front. But yeah,
- 1:39Speaker 4: will remain to be seen how competitive they will where
- 1:42Speaker 4: they will be with the drug with Eli Lily.
- 1:43Speaker 5: Yeah, it'd be interesting to see that yet, not just
- 1:48Speaker 5: the injectables but also pill forms of this obesity drug.
- 1:52Speaker 5: Next also seemed to have surprised the market the retailer
- 1:56Speaker 5: in the UK.
- 1:57Speaker 1: How did they manage that? They have?
- 1:58Speaker 4: Yeah, so they're first quarter came in a lot stronger
- 2:01Speaker 4: than expected sales wise, and they slightly, very slightly raise
- 2:05Speaker 4: their guidance for the full year. They are known for
- 2:07Speaker 4: doing that anyway, so that's somewhat expected. But they did
- 2:09Speaker 4: slightly raise their guidance and that is kind of easing
- 2:13Speaker 4: concern over the Middle East and the whole environment, and
- 2:17Speaker 4: that's really what's being focused on, that bit of positivity
- 2:19Speaker 4: from Next morning, pushing shares higher.
- 2:23Speaker 1: There are still kind of shadows on the horizon.
- 2:26Speaker 4: You could say, the Iram war is pushing up costs,
- 2:29Speaker 4: it's pushing up inflation, it's denting companies, savings and consumer confidence.
- 2:35Speaker 1: And Next really noted that this morning.
- 2:37Speaker 4: So they're expecting full year cost increases directly as a
- 2:41Speaker 4: result of the war, to reach forty seven million pounds.
- 2:43Speaker 4: They had before said fifteen million in March, which initially
- 2:46Speaker 4: covered the first three months of the war. Now they're
- 2:48Speaker 4: expecting a forty seven million pound hit as a result
- 2:52Speaker 4: of that. They're planning price increases internationally so not yet
- 2:55Speaker 4: in the UK, and cost savings unspecified cost savings, but
- 2:59Speaker 4: cost savings. So Bloomberg is Eligence saying that you know,
- 3:02Speaker 4: they've lifted their guidance, but that's showing that they're prepared
- 3:04Speaker 4: to raise prices to protect their own profits. But as
- 3:07Speaker 4: I say, the positivity element is being focused on a
- 3:10Speaker 4: shares are up and.
- 3:10Speaker 1: Louis briefly.
- 3:13Speaker 3: Liftans and jet fuel shortages came through with loss, but
- 3:17Speaker 3: less bad maybe than someone expected.
- 3:19Speaker 4: Yeah, so they've warned of, you know, these mounting risks,
- 3:22Speaker 4: surgeon fuel, fuel costs, possible supply crunch there as well,
- 3:28Speaker 4: but they say that they're going to mitigate this with
- 3:30Speaker 4: a bunch of things. So high revenue from tickets, further
- 3:32Speaker 4: efficiency again unspecified.
- 3:34Speaker 1: But shares rose because they did race rate guidance. Despite
- 3:37Speaker 1: all of.
- 3:37Speaker 2: That, the Stock Mover's report from Bloomberg Radio. Check back
- 3:42Speaker 2: with us throughout the day for the latest roundup of
- 3:44Speaker 2: companies making news on Wall Street and for the latest
- 3:47Speaker 2: market moving headlines. Listen to Bloomberg Radio Live, catch us
- 3:52Speaker 2: on YouTube, Bloomberg dot com, and on Applecarplay and Android
- 3:55Speaker 2: Auto with the Bloomberg Business app.